---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094862"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2026-08-12T20:05:37+00:00"
generated_at: "2026-08-12T20:07:39.981647+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q2 revenue up 23% to $18.5M; net loss narrows to $0.3M

## Summary
- Total revenues $18.5M for Q2 2026, +23% from $15.0M in Q2 2025; Emrosi sales $8.1M.
- GAAP net loss narrowed to $0.3M ($0.01/sh) from $3.8M ($0.16/sh) year ago.
- Non-GAAP EBITDA and Adjusted EBITDA positive for both three and six months ended June 30, 2026.
- Cash $25.6M at June 30, 2026 vs $24.1M at Dec 31, 2025; SG&A down $1.0M to $10.9M.
- Emrosi total prescriptions ~36,000 in Q2 2026, up from ~30,000 in Q1 and ~27,000 in Q4 2025.

## SEC filing metadata
- accession: 0001104659-26-094862
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2026-08-12T20:05:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/0001104659-26-094862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094862
- JSON: https://secwatch.observer/filing/0001104659-26-094862.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.